<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618579</url>
  </required_header>
  <id_info>
    <org_study_id>TB-402-003</org_study_id>
    <nct_id>NCT00618579</nct_id>
  </id_info>
  <brief_title>Effects of LMWH in Healthy Subjects Treated With TB-402 and Effects of TB-402 in Healthy Subjects Treated With Warfarin</brief_title>
  <official_title>A Randomised, Controlled Study Investigating the Safety and Anticoagulant Activity of Administration of Low-molecular-weight Heparin in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402 and the Safety and Anticoagulant Activity of Administration of TB-402 in Healthy Male Subjects Treated With Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of LMWH in healthy male subjects treated with TB-402 and administration of
      TB-402 in healthy male subjects treated with warfarin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anticoagulant activity assessed by aPTT, PT, TGAs and FVIII:c</measure>
    <time_frame>To study end</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in safety parameters over time, PK parameters estimated by NCA, effect of LMWH in TB-402 treated subjects assessed by anti factor Xa (LMWH arm)</measure>
    <time_frame>To study end</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LMWH arm - active LMWH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LMWH arm - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin arm - active warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin arm - control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects</intervention_name>
    <description>Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin</description>
    <arm_group_label>LMWH arm - active LMWH</arm_group_label>
    <arm_group_label>LMWH arm - placebo</arm_group_label>
    <arm_group_label>Warfarin arm - active warfarin</arm_group_label>
    <arm_group_label>Warfarin arm - control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:

          -  Males 18 to 45 years of age

          -  Healthy according to medical history, physical exam, ECG, blood pressure and heart
             rate, and laboratory profile of blood and urine

        Exclusion Criteria include:

          -  Self or family history of cardiovascular or pulmonary disorder, or coagulation or
             bleeding disorders or reasonable suspicion of vascular malformations e.g. cerebral
             haemorrhage, aneurysm or premature stroke

          -  History of important bleeding episodes

          -  Previous allergic reaction to immunoglobulin

          -  Present or previous history of severe allergy, for example asthma or anaphylactic
             reactions

          -  FVIII:C &lt;50% at screening

          -  Clinically significant out of range values for any coagulation test during screening

          -  Received prescribed medication, over the counter medication or herbal medicines within
             14 days of receipt of TB-402
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Jensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cyncron CRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cyncron CRU</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interaction with LMWH or warfarin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

